Diabetic Nephropathy Care
Diabetic Nephropathy (Diabetic Kidney Disease) in Secunderabad — Detect It Early, Slow It Significantly
At a glance
Condition
Diabetic Nephropathy — kidney damage caused by diabetes mellitus (Type 1 or Type 2)
India context
Diabetes is the leading single cause of chronic kidney disease and kidney failure in India. Every diabetic person is at risk.
Can it be reversed?
Early diabetic kidney damage (microalbuminuria) can be reduced and sometimes reversed with intensive treatment. Established nephropathy can be significantly slowed but not reversed.
KIMS model
Joint diabetic kidney disease clinic — nephrologist and endocrinologist co-manage each patient. Same appointment, same campus, one coordinated plan.
Key Interventions & Clinical Excellence
The following diagnostics and therapies are the primary focus at KIMS for changing patient outcomes and preventing progression to kidney failure.
★ Most important test: Urine ACR
Urine albumin-creatinine ratio (ACR) — detects kidney damage 5–10 years before creatinine rises or symptoms appear. Every diabetic should have this test annually.
★ Latest treatment: SGLT2 Inhibitors
Empagliflozin, dapagliflozin, etc. — kidney-protective even in patients with already reduced kidney function. Now first-line at KIMS for diabetic nephropathy.
Specialist at KIMS
DM Nephrology-qualified nephrologists · Award-winning nephrology programme (Times Healthcare Achievers)
Appointments
040 - 44885000 · assistance@kimshospitals.com — respond within 24 hours
What is diabetic nephropathy?
Diabetic nephropathy is progressive kidney damage caused by chronically elevated blood sugar. The kidneys contain approximately one million tiny filters called glomeruli — networks of microscopic blood vessels that separate waste from the blood. Sustained high blood sugar damages these vessels, causing them to thicken, scar, and leak protein (albumin) into the urine. Over years to decades, this damage accumulates: the filtration rate falls, waste products build up, and eventually — in patients who are not treated — the kidneys fail.
Approximately 30–40% of people with diabetes develop diabetic nephropathy. It is the leading cause of chronic kidney disease and kidney failure in India. The insidious nature of diabetic nephropathy is that it causes no symptoms in its early stages — it is completely silent while the damage is accumulating. This is why a specific blood and urine test is required to detect it, and why waiting for symptoms is too late.
If a patient with known kidney disease suddenly becomes confused, extremely breathless, has markedly reduced or no urine output, or is in severe pain — go to KIMS Emergency immediately or call 040 - 44885000. Severe hyperkalaemia (dangerously high potassium), uraemia (waste build-up affecting the brain), and pulmonary oedema (fluid in the lungs) are life-threatening complications of untreated kidney failure that require emergency treatment.
The test that detects kidney damage 5–10 years early — urine ACR
The urine albumin-creatinine ratio (ACR) is the single most important test for detecting diabetic kidney damage at its earliest and most treatable stage. It measures the amount of albumin (protein) leaking into the urine — the first detectable sign of glomerular damage, appearing years before the creatinine level rises or symptoms develop. Every person with diabetes should have this test annually. If you have diabetes and have not had a urine ACR test in the past 12 months — please book one today.
| Urine ACR result & meaning | Action at KIMS |
|---|---|
| Under 3 mg/mmol (< 30 mg/g) — Normal. No detectable kidney damage from diabetes. | Annual urine ACR, creatinine, HbA1c, and blood pressure check. Blood sugar and BP optimisation. Lifestyle guidance. |
| 3–30 mg/mmol (30–300 mg/g) — Microalbuminuria. Early kidney damage — kidney leaking small amounts of protein. | Start ACE inhibitor or ARB. Intensify blood sugar control (HbA1c < 7%). Add SGLT2 inhibitor if eligible. Review every 3–6 months. |
| Over 30 mg/mmol (> 300 mg/g) — Macroalbuminuria / Overt nephropathy. Significant protein loss, kidney function likely falling. | Maximum RAAS blockade. SGLT2 inhibitor + finerenone if eligible. Strict BP control. Dietary management. Nephrology-led care plan. |
How diabetic nephropathy progresses — the five stages
Diabetic nephropathy progresses through five recognised stages. Early stages are detectable and treatable; later stages require more intensive management. The rate of progression varies dramatically between individuals — and is directly influenced by blood sugar control, blood pressure management, and the use of kidney-protective medications.
| Stage | What is happening | KIMS approach |
|---|---|---|
| Stage 1 — Hyperfiltration | The kidneys work harder than normal — eGFR is elevated. No protein in urine. No symptoms. | Annual urine ACR + creatinine. Blood sugar control. Blood pressure target < 130/80. No medications for the kidney yet — prevention focus. |
| Stage 2 — Silent damage | Structural damage to glomeruli is developing. Urine ACR still normal. eGFR normal. No symptoms. | Annual monitoring. Intensify HbA1c control (target <7%). Blood pressure < 130/80 with RAAS blockade. |
| Stage 3 — Microalbuminuria | Small amounts of albumin detected in urine (ACR 3–30 mg/mmol). eGFR still normal or mildly reduced. This stage is reversible with treatment. | ACE inhibitor or ARB first-line. SGLT2 inhibitor (empagliflozin or dapagliflozin) initiated — reduces proteinuria and slows CKD progression independently of glucose. Blood sugar intensive control. |
| Stage 4 — Overt nephropathy | Significant proteinuria (ACR >30 mg/mmol). eGFR progressively falling. Blood pressure rising. Swelling may develop. | Maximise RAAS blockade. SGLT2 inhibitor + finerenone if tolerated. Strict blood pressure control (<130/80). Dietary protein and potassium management. CKD complications monitoring. |
| Stage 5 — Kidney failure (ESRD) | eGFR below 15. Kidney function cannot sustain life without replacement. | Renal replacement therapy: haemodialysis, peritoneal dialysis, or kidney transplantation — all available at KIMS. Transition planned from Stage 4 onwards. |
How diabetic nephropathy is treated at KIMS Secunderabad
Diabetic nephropathy treatment has three simultaneous goals: control the underlying diabetes (prevent further damage), actively protect the kidneys with specific kidney-protective medications, and manage the complications of reduced kidney function as they develop.
1 — Blood sugar control — the foundation
HbA1c target at KIMS: under 7% for most patients with early diabetic nephropathy. The target is individualised — for older patients, those with frequent hypoglycaemia, or those with advanced CKD, a slightly higher target (7.5–8%) reduces the risk of dangerous low blood sugar episodes. At KIMS, the endocrinologist co-manages blood sugar medications alongside the nephrologist — particularly important because some diabetes medications (metformin, sulphonylureas, certain SGLT2 inhibitors) require dose adjustment or cessation as kidney function falls. Having both specialists at the same appointment prevents the dangerous situation of one doctor prescribing a medication the other does not know about.
2 — SGLT2 inhibitors — the revolution in diabetic kidney protection
SGLT2 inhibitors (empagliflozin — Jardiance, and dapagliflozin — Forxiga) are now first-line kidney-protective treatment for diabetic nephropathy at KIMS — independently of their glucose-lowering effect. Large randomised controlled trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY) have demonstrated that SGLT2 inhibitors reduce the risk of kidney failure by 30–40%. SGLT2 inhibitors work on the kidneys directly — reducing intraglomerular pressure, decreasing proteinuria, and reducing inflammation and fibrosis within kidney tissue. They are effective across a wide range of kidney function levels. At KIMS, this is standard of care even when eGFR is already reduced, provided no contraindications exist.
3 — RAAS blockade — ACE inhibitors and ARBs
ACE inhibitors (ramipril, enalapril, lisinopril) and ARBs (losartan, telmisartan, irbesartan) reduce the pressure within the kidney's glomeruli and significantly reduce proteinuria. They are first-line blood pressure medication for all diabetic nephropathy patients regardless of blood pressure level. At KIMS, RAAS blockade is initiated at the microalbuminuria stage and titrated to the maximum tolerated dose. The urine ACR and potassium level are monitored after any dose change to ensure safety and efficacy.
4 — Finerenone — the newest kidney-protective medication
Finerenone (Kerendia) is a selective mineralocorticoid receptor antagonist that reduces kidney inflammation and fibrosis independently of SGLT2 inhibitors and RAAS blockade. Clinical trials (FIDELIO-DKD and FIGARO-DKD) demonstrated significant reductions in CKD progression. At KIMS, finerenone is now considered alongside SGLT2 inhibitors for appropriate patients with Stage 3–4 diabetic nephropathy — providing a third layer of kidney protection beyond standard ACE inhibitors.
5 — Blood pressure control — the non-negotiable
Target blood pressure in diabetic nephropathy: below 130/80 mmHg — stricter than the general population target. Uncontrolled hypertension in a diabetic patient doubles the rate of kidney function decline. At KIMS, blood pressure is monitored at every clinic visit and medication is adjusted proactively. Home blood pressure monitoring is taught to all nephropathy patients because 24-hour control is essential for preventing long-term damage.
6 — Diet — individualised, not generic
The dietary advice for diabetic nephropathy depends on the stage and the specific complications present. KIMS provides a renal dietitian assessment for every patient. General principles include: reducing salt aggressively (under 5g per day) to protect blood pressure; moderating protein intake (0.8 g/kg body weight); limiting high-potassium foods if levels are rising; and managing phosphate from Stage 4. Patients receive a personalised plan tailored to their nutritional status.
Why choose KIMS Secunderabad for diabetic nephropathy care?
KIMS offers a specialized, integrated approach to diabetic kidney disease that combines world-class expertise with a unique joint-clinic model to ensure the best possible patient outcomes.
Joint diabetic kidney disease clinic
Nephrology and endocrinology at one appointment. This is the KIMS model that no competitor in Secunderabad or Hyderabad replicates as a formal, co-scheduled programme. The nephrologist manages kidney function and protective medications, while the endocrinologist manages blood sugar and metabolic risk. One appointment. One coordinated plan. One set of monitoring targets.
DM Nephrology-qualified specialists
The highest qualification in Indian nephrology. KIMS's consulting nephrologists hold DM (Nephrology). Dr. E. Ravi ranked first statewide in the DM Nephrology super-speciality entrance examination in 2009 — bringing the highest level of specialist training to the management of complex nephropathy cases, ensuring precise medication adjustments and accurate trajectory tracking.
SGLT2 inhibitors and finerenone monitoring
Many patients in general clinics are never offered SGLT2 inhibitors for kidney protection because of uncertainties regarding dose adjustment in CKD. At KIMS, our kidney specialists specifically initiate and monitor these medications (including the latest therapies like finerenone) as a standard of care to reduce the risk of kidney failure by 30–40%.
Times Healthcare Award for Nephrology
External validation of KIMS's nephrology programme quality. This is the only independently judged nephrology award in Hyderabad. It serves as an objective assessment of our clinical excellence and patient care standards, rather than a self-declaration.
NABL-accredited laboratory
Diabetic nephropathy management depends entirely on diagnostic accuracy. Our NABL-certified laboratory ensures that HbA1c, urine ACR, creatinine, and eGFR results are precise. An incorrectly measured urine ACR can delay the detection of nephropathy by years; at KIMS, we eliminate that risk.
Integrated Metabolic Risk Management
Diabetic nephropathy does not exist in isolation. Our team manages the 'cardio-renal-metabolic' spectrum together, addressing blood pressure, cholesterol, and weight management as part of the kidney-protection strategy to reduce both kidney failure and cardiovascular events.
Book a Diabetic Kidney Screening at KIMS
Our diabetic nephropathy specialists at KIMS Secunderabad
Frequently Asked Questions
The earliest sign of diabetic kidney damage is protein leaking into the urine — detectable years before any symptoms appear and years before the creatinine level rises. This is measured by the urine albumin-creatinine ratio (ACR) test — a simple urine test that should be done annually in every person with diabetes. An ACR of 3 mg/mmol or above indicates early kidney damage (microalbuminuria). If you have diabetes and have not had a urine ACR test in the past 12 months — book one today. At KIMS Secunderabad, we perform urine ACR as part of every diabetic nephropathy assessment.
At the earliest stage — microalbuminuria — diabetic kidney damage can sometimes be significantly reduced and occasionally reversed entirely with intensive blood sugar control, blood pressure management, and SGLT2 inhibitor therapy. Established diabetic nephropathy (higher levels of proteinuria with falling eGFR) cannot be reversed — but it can be significantly slowed. The goal of specialist care at KIMS is to preserve kidney function so substantially that the patient never reaches dialysis, or delays it by many years.
SGLT2 inhibitors — empagliflozin (Jardiance) and dapagliflozin (Forxiga) — are a class of medications shown to slow the progression of diabetic kidney disease by 30–40%, independently of their blood sugar-lowering effect. They reduce pressure within the kidney's filtering units and decrease protein leakage. They are now first-line kidney-protective treatment at KIMS. Many patients in general clinics are never offered these because their kidney-protective benefit has only been widely recognised in the past five years.
Both — and ideally both together. Diabetic nephropathy sits at the intersection of endocrinology and nephrology. Seeing them separately often leads to fragmented care or conflicting targets. At KIMS Secunderabad, we manage this through a joint clinic model: the nephrologist and endocrinologist see you together at the same appointment to create one coordinated treatment plan, which is the international standard of care.
A raised creatinine suggests reduced kidney function, but it does not automatically mean kidney failure is imminent. Creatinine is interpreted as eGFR. An eGFR of 45–59 (Stage 3A), for example, means the kidneys are less efficient, but most patients can be maintained at this level for years with good management. At KIMS, we track your eGFR trajectory over time rather than focusing on a single absolute value.
Dietary advice depends on the kidney stage. Generally: reduce salt substantially (under 5g per day); keep protein intake moderate (0.8 g/kg body weight); and limit ultra-processed foods. From Stage 3B onward, you may need to limit high-potassium foods (bananas, tomatoes) and phosphate-rich foods (dairy, processed meats). The KIMS renal dietitian provides a personalised plan because what is appropriate at Stage 2 may be harmful at Stage 4.
There is no cure that reverses established scarring, but kidney function can be preserved for a very long time. With current treatments—combining SGLT2 inhibitors, RAAS blockade, finerenone, and strict control of blood sugar and pressure—many patients can stabilise their kidney function at Stage 3 for 10, 15, or even 20 years. Starting specialist care at Stage 2 or early Stage 3 provides a dramatically better outcome than starting at Stage 4.
KIMS Secunderabad offers a joint nephrologist-endocrinologist clinic—a model not formally offered by other regional hospitals. Our DM-qualified nephrologists (including Dr. E. Ravi, ranked first statewide) specifically monitor medications like SGLT2 inhibitors for kidney protection. KIMS is recognized by Times Healthcare Achievers as the Best Hospital of the Year in Nephrology and is NABH/NABL accredited.